Skip to main content

Carboplatin Solution for Injection Shortage

Last Updated: September 24, 2024
Status: Current

Products Affected - Description
    • Carboplatin solution for injection, Accord, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 16729-0295-33
    • Carboplatin solution for injection, Accord, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 16729-0295-31
    • Carboplatin solution for injection, Fresenius Kabi, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 63323-0172-60
Reason for the Shortage
    • Accord has carboplatin on shortage due to manufacturing delays.
    • Eugia has carboplatin injection available.
    • Fresenius Kabi has carboplatin injection available.
    • Ingenus has carboplatin injection available.
    • Pfizer has carboplatin on shortage due to increased demand.
    • Teva has carboplatin injection available.
Available Products
    • Carboplatin solution for injection, Accord, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 16729-0295-34
    • Carboplatin solution for injection, Accord, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 16729-0295-12
    • Carboplatin solution for injection, Eugia US, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 55150-0335-01
    • Carboplatin solution for injection, Eugia US, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 55150-0386-01
    • Carboplatin solution for injection, Ingenus Pharmaceuticals, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 50742-0447-45
    • Carboplatin solution for injection, Ingenus Pharmaceuticals, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 50742-0448-60
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 61703-0339-22
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 61703-0339-50
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 61703-0339-18
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 61703-0339-56
    • Carboplatin solution for injection, Teva, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 00703-4246-01
    • Carboplatin solution for injection, Teva, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 00703-4248-01
    • Carboplatin solution for injection, Teva, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00703-4244-01
    • Carboplatin solution for injection, Teva, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 00703-4239-01

Estimated Resupply Dates

    • Accord has carboplatin 10 mg/mL 5 mL and 15 mL vials on back order and the company cannot estimate a release date.
    • Fresenius Kabi has short-dated carboplatin 10 mg/mL 60 mL vials available with an expiration date of < 7 months.

Implications for Patient Care

Alternative Agents & Management

    • Consider evaluating the health-care system's total supply of carboplatin before beginning patients on combination chemotherapy regimens containing carboplatin. If adequate supplies are not available, select an alternative regimen.
    • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for carboplatin.
    • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
    • Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.pdf
    • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.

Updated

Updated September 24, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 28, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.